Pediatric obesity is a serious medical condition associated with significant comorbidities during childhood and adulthood. Lifestyle modifications are essential for treating children with obesity, yet many have insufficient response to improve health with behavioral approaches alone. This review summarizes the relatively sparse data on pharmacotherapy for pediatric obesity and presents information on obesity medications in development. Most previously studied medications demonstrated, at best, modest effects on body weight and obesity-related conditions. It is to be hoped that the future will bring new drugs targeting specific obesity phenotypes that will allow clinicians to use etiology-specific, and therefore more effective, anti-obesity therapies.
INTRODUCTION

Prevalence of pediatric obesity and its complications: implications for intervention
Childhood obesity (defined as body mass index (BMI) X95th percentile for age and sex standards by the US Centers for Disease Control) has increased alarmingly over the past four decades, with almost 17% of US children and adolescents considered obese. 1 Globally, obesity is considered one of the leading risk factors contributing to morbidity and mortality. 2 Although there is some evidence that childhood obesity prevalence rates in the United States, 1, 3 Australia, China and some European countries [4] [5] [6] [7] [8] may have stabilized, they remain unacceptably high. 2, [9] [10] [11] Childhood obesity is not only associated with a higher risk of morbidity and premature death in adults, but is also accompanied by many comorbid medical conditions during childhood. [12] [13] [14] [15] [16] [17] [18] The weight-related complications that arise during childhood, added to the risks for morbidity and mortality imparted to adults who were obese as children, 19 -21 make development of effective treatments imperative.
Role of lifestyle modification interventions in the treatment of pediatric obesity Lifestyle modification interventions, including behavioral treatment, diet modification and physical activity, are the cornerstones of primary and secondary prevention/treatment of pediatric obesity. 22 Some studies have shown long-lived effects on pediatric overweight 23 specially from family-based or other behavioral treatments 24 without adverse effects on growth and development. 25 A Cochrane review and meta-analysis suggested some efficacy for such lifestyle modifications after 12 months of treatment with a BMI s.d. score change of À 0.04 and À 0.14, respectively, for children below and over 12 years of age. 24 For young children (5-12 years old), a considerable effect size of 0.89 (reduction in percentage of overweight) has been reported. 26, 27 However, such interventions have shown relatively limited success among severely obese children and adolescents in either reduction of body weight or improvement of medical outcomes. 22, 24, 28, 29 Altogether, success of such interventions is closely related to external factors such as more family involvement, greater socioeconomic status and better cultural adaptation, which may not be attainable in every circumstance. [30] [31] [32] As a result, there is considerable interest in combining lifestyle modification with more intensive strategies, including pharmacotherapy, to ameliorate pediatric obesity. 33 Objectives In this paper, we critically review the limited available data for the safety and efficacy of medications that have been studied for the treatment of obesity in children and adolescents, including drugs approved for pediatric obesity treatment, those used off-label for obesity as well as drugs under development for treatment of obesity in adults (Table 1) .
Data synthesis A PubMed search was conducted with no limitation for year of publication to find reports investigating antiobesity drugs, utilizing the keywords 'children' or 'adolescents', 'obesity,' 'appetite' or 'satiety', 'drug' or 'pharmacotherapy' and 'clinical trial' or 'meta-analysis'. The primary search resulted in 1296 articles for which the titles and/or abstracts were examined to determine if they complied with the search criteria. Automated searches were supplemented by examination of expert recommendation reports and bibliographic references from included research studies, as well as searches for the names of medications approved by the Food and Drug Administration (FDA) for weight-loss treatment or known to be used off-label for weight loss. Although the emphasis of this review is primarily on outcomes available from placebo-controlled, double-blind, randomized clinical trials, if other data were not available, we also present the results of open-label studies, as well as case series that report weight reduction as a primary or secondary endpoint of the study. Included pediatric clinical trials are enumerated in Supplementary Table 1 . This review summarizes study design and clinical results achieved with each drug, with a discussion of methodology including subject characteristics, type and duration of intervention and adverse effects.
A brief appraisal of treatment options that are currently under investigation in adults will also be presented, based on a search conducted using 'obesity,' 'appetite or satiety', 'drug or pharmacotherapy' and 'clinical trial' or 'review' that was supplemented by manual searches for current and new drugs for adults (Table 1) . 35 There are no pediatric experimental data establishing how long nonpharmacologic interventions should be attempted before medication is prescribed; typically, a 6-month trial is used. 34 As observed in adults, 36 greater weight reduction has been reported among adolescents prescribed weight-loss medications who adhered to lifestyle interventions. 37 There are no pediatric data suggesting that obesity pharmacotherapy can be effectively prescribed without an accompanying lifestyle modification program.
Some experts believe that obesity pharmacotherapy should be reserved for children and adolescents with high BMI who also demonstrate an obesity-related comorbidity such as dyslipidemia, hypertension, insulin resistance, fatty liver disease or obstructive sleep apnea. 34, 38 The argument made is that the potential benefits are more likely to outweigh the potential risks of pharmacotherapy among those who already manifest complications of excess weight. Not all pediatric obesity drug treatment trials or published recommendations 33, 39 have required presence of obesity-related comorbidities. 35 When the USFDA approves a medication for a specific indication in adults, the lower age limit for approved use is generally set at 16 years.
40 Such medications will be described in this review as approved for adults. At the present time, only one agent (orlistat) holds FDA approval to treat obesity among adolescents aged 12-16 years; no weight-loss medications are approved for use in children o12 years old.
CURRENT PHARMACOTHERAPEUTIC OPTIONS FOR OBESITY TREATMENT Drugs decreasing energy intake Classical centrally acting anorexiant medications. The classical anorexiants act within the central nervous system to alter the release and reuptake of neurotransmitters long known to be implicated in appetite: norepinephrine, serotonin and dopamine. 41 No weight-loss medication with these mechanisms of action is currently approved for pediatric use and no available data support their long-term (41 year) safety or efficacy in pediatric populations.
(a) Appetite suppressants with primarily adrenergic effects: Phentermine, 42 diethylpropion 43 and mazindol [44] [45] [46] [47] are anorexiants approved by the FDA for short-term use in adults that exert anorexiant effects primarily by increasing adrenergic tone. 48 They decrease food intake and also increase resting energy expenditure. 49 Phentermine and diethylpropion are chemically related to amphetamines. 50 Phentermine, mazindol and diethylpropion are Drug Enforcement Administration (DEA) schedule IV controlled substances, indicating a relatively low potential for abuse. 51 Mazindol is not currently available in the United States, and phenylpropanolamine 52 has been withdrawn because of increased risk of hemorrhagic stroke. 53 Other drugs such as benzphetamine and phendimetrazine are also approved for short-term use with caution because of the potential risks such as pulmonary hypertension and valvular disease. 54, 55 Only small pediatric trials using phentermine 42, 56 or diethylpropion 43, 57 that lasted no more than 12 weeks have been reported. The adverse effect profiles of phentermine and diethylpropion in adults include insomnia, restlessness and euphoria, palpitations, hypertension and cardiac arrhythmias, dizziness, blurred vision and ocular irritation. Because of the lack of long-term pediatric treatment trials showing safety and efficacy, these drugs are not recommended as weight loss medications in youth.
(b) Appetite suppressants with primarily serotonergic effects: There are several drugs for which pediatric trials exist that affect appetite primarily by increasing serotonergic release or inhibiting reuptake, 48, 50 including fluoxetine, chlorphentermine, fenfluramine and its stereoisomer, dexfenfluramine. [58] [59] [60] [61] [62] [63] None of these drugs are currently FDA-approved for weight loss and most have been removed from the US market. The longest pediatric trial studied fenfluramine versus placebo for 12 months in Brazilian adolescents. 61 Among those completing the study, fenfluramine-treated adolescents reportedly decreased BMI by À 5.1 kg m À 2 (placebo treated: À 1.3 kg m À 2 , Po0.05). Fenfluramine and dexfenfluramine were withdrawn in 1997, when cardiac valvulopathies similar to those seen in the carcinoid syndrome were found after their use. 64, 65 Serotonergic anorexiant agents were also associated with an increased incidence of primary pulmonary hypertension. 66 Other adverse effects of these agents included headache, abdominal pain, drowsiness, insomnia, dry mouth, increased activity and irritability. 67 (c) Agents with primarily dopaminergic effects: Amphetamines, including methylphenidate and dextroamphetamine (DEA Schedule II controlled substances), increase dopaminergic tone by inhibiting dopamine reuptake 57, 69 . Acute studies demonstrate their ability to suppress appetite in obese adults, 69 and anorexia is a frequently observed side effect when such medications are used in pediatric patients with attention deficit disorder. 70, 71 Because of their adverse effect profile (agitation, insomnia, tachycardia, hypertension and hyperhidrosis), abuse potential 72 and the absence of trials showing long-term weight-loss efficacy, these agents are not recommended or approved for obesity management.
(d) Agents with action at multiple monoamine receptors: Sibutramine, which inhibits norepinephrine and serotonin reuptake, was FDA approved in 1997 for weight loss and maintenance of weight loss in adults with a BMI X30 or X27 kg m À 2 with comorbidities. 73 Adverse effects included increases in pulse and blood pressure. Sibutramine was voluntarily withdrawn from use in 2010 when a greater incidence of cardiovascular events was found among adults at high risk for cardiovascular disease who took the drug.
Sibutramine was never approved for use in children o16 years of age, 74, 75 but it is one of the best-studied weight-loss medication in adolescents. Ten reports 37, [76] [77] [78] [79] [80] [81] [82] [83] [84] from eight randomized controlled trials 37, 76, 78, 79, [81] [82] [83] [84] and two open-label studies 77, 80 investigated the efficacy of sibutramine for weight loss in obese adolescents. Sibutramine 5-15 mg day À 1 was administered as an adjunct to behavioral therapy with or without dietary intervention for 6-to 12-month periods and led to À 2.9 to À 3.6 kg m À 2 decreases in BMI. The largest trial was conducted on 498 obese adolescents randomized 3:1 to receive either sibutramine or placebo, in addition to caloric restriction and behavioral therapy for 12 months. 78, 82 Sibutramine was initiated at 10 mg day À 1 and was increased to 15 mg day À 1 in the 48% of subjects who showed o10% BMI reduction. This 1-year therapy resulted in a 2.9 kg m À 2 BMI reduction in the sibutramine group (versus 0.3 kg m À 2 for placebo). Among those receiving sibutramine plus behavioral therapy, 62.3% achieved a 45% BMI reduction, versus 38.8% for placebo plus behavioral therapy. Treatment with sibutramine was associated with greater improvements in waist circumference, triglycerides, high-density lipoprotein cholesterol, insulin levels and insulin sensitivity. The effect of sibutramine on adolescent cardiovascular health was a matter of concern when the first pediatric data became available. 85 Greater reductions in cardiovascular variables, including change in systolic and diastolic blood pressure, and pulse rate were generally seen in placebo-treated adolescents despite the greater weight loss in the sibutramine-treated groups. Statistically significant differences favoring placebo were found for systolic blood pressure, 37 Pharmacotherapy for childhood obesity R Sherafat-Kazemzadeh et al diastolic blood pressure 78, 84 and heart rate. 37, 78 Adult studies confirmed sibutramine increases blood pressure and heart rate. 86, 87 In September 2010, SCOUT (Sibutramine Cardiovascular Outcomes Trial), a multinational, randomized, placebo-controlled trial conducted in 16 countries, with a mean of 3.4 years of duration designed to assess clinical outcome in subjects with high risk of cardiovascular events, 88 found that rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively. The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group. 88 These findings resulted in an FDA request to withdraw sibutramine from the US market. 89 Apart from cardiovascular outcomes, other adverse effects included dry mouth, insomnia, constipation, headache and cholelithiasis. Sibutramine was contraindicated in individuals with pre-existing psychiatric disorders. 74 Other contraindications included concurrent use of monoamine oxidase inhibitors or selective serotonin reuptake inhibitors. 90 Drugs in development or used off-label that may act centrally as anorexiant medications. Emerging knowledge of the physiologic processes that control food intake over the past 15 years has led to a greater understanding of both short-term signals that are involved in meal initiation and termination and longer-term regulators of energy balance. The adipocyte-derived hormone leptin 91 conveys information about the status of adipocyte triglyceride content, as well as the energy and macronutrient composition of recent intake, to brain regions that control energy intake. [92] [93] [94] Low concentrations of circulating leptin have been found to produce defects in both satiation and satiety, leading to hyperphagia. 95 In the presence of leptin deficiency, activity increases in hypothalamic appetite-regulating neurons that release orexigenic peptides, and decreases in neurons that release anorexigenic factors. 96 Hormones and neurotransmitter systems involved in modulating the hypothalamic leptin signaling pathway have therefore been investigated for their potential ability to alter body weight in obese individuals.
(a) Leptin: The discovery of leptin was received with great anticipation as a potential antiobesity therapy because of its ability to reverse excess adiposity in rodent models characterized by leptin deficiency. [97] [98] [99] Indeed, leptin dramatically reduces body fat, suppresses appetitive behaviors and improves other leptinresponsive endocrine and metabolic abnormalities in children and adults with congenital leptin deficiency. [100] [101] [102] [103] Open-label trials in pediatric and adult patients with leptin insufficiency due to congenital lipodystrophies also demonstrated long-term improvements in metabolism, 104 as did placebo-controlled trials in leptin-insufficient women with hypothalamic amenorrhea. 105 However, studies carried out in nonleptin-deficient adults have found relatively small effects on body weight, which limits leptin's usefulness as a stand-alone antiobesity medication in those without leptin insufficiency. 106, 107 In adults who have undergone substantial weight reduction, there is suggestive evidence that leptin treatment to restore serum leptin concentrations to preweight loss values may reverse the subtle muscular, neuroendocrine and autonomic adaptations to the weightreduced state that may predispose such individuals to regain their lost weight. [108] [109] [110] [111] [112] No trials have assessed leptin's effects in nonleptin-deficient children during weight reduction or in the weight-reduced state.
(b) Bupropion: Bupropion 113 is an antidepressant that inhibits presynaptic reuptake of both norepinephrine and dopamine. It is structurally close to the appetite suppressant diethylpropion. 114 Pooled data meta-analysis of five studies among adults reported a pooled random-effect estimate of total weight loss of 4.44 kg for Bupropion-treated adults as compared with 2.77 kg for placebo at a mixed end point of 6 to 12 months; 115 similar mean weight reduction was reported in a review of trials on patients with major depression. 116 No pediatric randomized controlled trials of bupropion examining its effects on body weight have been published, although some short-term open-label studies suggest its use may be associated with small amounts of weight loss in adolescents. 117, 118 (c) Lorcaserin: Lorcaserin is a selective 5-HT 2C receptor agonist that acts primarily in the central nervous system to inhibit feeding behavior. 119 In adults, a 3182-person phase III multicenter clinical trial (BLOOM) showed that 47.5% of those treated with lorcaserin, versus 20.3% of those given placebo, lost X5% of baseline body weight after 1 year; the average weight loss was 5.8 kg for lorcaserin versus 2.2 kg for placebo. 120 A second trial (BLOSSOM) 121 found similar efficacy among 4008 patients. Adult patients with type 2 diabetes also decreased weight after treatment. 122 No pediatric trials have been reported. The common adverse events in both trials included headache, nausea and dizziness. The FDA approved lorcaserin, 10 mg b.i.d., in June 2012 to treat adults with BMI X30 or X27 kg m À 2 accompanied with at least one comorbid condition such as hypertension, type 2 diabetes mellitus or dyslipidemia. 123, 124 Although lorcaserin use was not associated with valvular diseases in its placebo-controlled trials, it was recommended to be used with caution in patients with congestive heart failure. The company was required by the FDA to conduct long-term cardiovascular outcomes trial. 123, 124 The package insert specifies that patients who have not lost X5% of baseline body weight by 12 weeks should discontinue lorcaserin.
(d) Tesofensine: Tesofensine is a triple monoamine reuptake inhibitor, blocking the presynaptic uptake of noradrenaline, dopamine and serotonin. A 24-week phase II trial of 203 adults reported weight losses of up to 10% of body weight (versus 2% in placebo) in tesofensine-treated adults. 125 Body weight decreased 2.2 kg in the placebo group and decreased 6.7-12.8 kg with different dosages of tesofensine. 125 Tesofensine increases satiety and may increase energy expenditure. 126, 127 No pediatric studies have been reported.
(e) Cannabinoid (CB) receptor inhibitors: Stimulation of central CB 1 receptors increases appetite and fat deposition. Clinical trials of rimonabant, a selective endocannabinoid (CB 1 receptor) antagonist, indicated beneficial effects on weight, waist circumference, serum lipids, C-reactive protein and glycemic control in adult patients with type 2 diabetes. 128, 129 The major adverse effects of rimonabant included nausea, anxiety and depression. 130 The FDA did not approve rimonabant in 2007 because of concerns about neuropsychiatric adverse effects, particularly an increase in suicidality. Approved as a weight-loss medication in Europe in 2006, rimonabant was withdrawn by the European Medicines Agency in 2009 because of an increase in psychiatric adverse effects. 131 Clinical development of rimonabant as well as other centrally acting CB 1 inhibitors such as taranabant and otenabant was suspended as a result of this adverse event profile. 73, 132, 133 More recent findings on CB 1 receptor antagonism in the liver, adipocytes, muscle and pancreas have raised hopes for potentially new generation of peripherally acting CB 1 receptor inhibitors for treatment of obesity and its comorbid conditions such as fatty liver, insulin resistance and dyslipidemia. [134] [135] [136] [137] (f) Topiramate: Topiramate is a GABA-ergic anticonvulsant drug that was fortuitously found to induce weight loss in patients with epilepsy. Among obese adults, data from trials suggested the possibility of substantial weight loss (4.5 to 16.36 kg for topiramate versus 1.7 to 8.6 kg for placebo). 138 Topiramate could also abrogate antipsychotic-induced weight gain. 139 Common adverse events include paresthesias, taste impairment and psychomotor disturbances including difficulties with concentration and sedation. In children, topiramate has been studied for the treatment of epilepsy 140 and migraine, 141 where its use is associated with 1-2 kg decreases in body weight versus placebo.
Pharmacotherapy for childhood obesity R Sherafat-Kazemzadeh et al A limited number of open-label case series [142] [143] [144] have suggested potential improvements in body weight among children with antipsychotic-associated weight gain and in two extremely obese adolescent boys with Duchenne Muscular Dystrophy. 145 Concerns over the impairment of cognitive function at dosages similar to those used to treat seizure disorders will likely limit its use as a stand-alone agent; 146 no controlled trials restricted to obese children or adolescents have been reported. It is also important to note that there is concern that the risk for cleft lip with or without cleft palate is increased in children born to mothers who used topiramate during pregnancy. 147, 148 (g) Amylin: Amylin is a pancreatic b-cell hormone that reduces food intake, slows gastric emptying and reduces postprandial glucagon secretion in humans. Many of its hypophagic actions in rodents appear dependent on direct activation of noradrenergic neurons within the area postrema. 149 Amylin receptors in hind brain are hetero-oligomers with calcitonin receptors; 150 amylin interacts with other signals involved in the short-term control of food intake, including cholecystokinin, glucagon-like peptide 1 (GLP-1) and peptide YY, and has been shown to decrease expression of orexigenic neuropeptides in the lateral hypothalamus. 149 Pramlintide, a synthetic analog of amylin, is approved for the treatment of both type 1 and type 2 diabetes and produces small weight losses in obese and diabetic adults. 151, 152 One study of adults with and without type 2 diabetes found a placebo-subtracted weight loss of up to 2.7 kg after 16 weeks of thrice-daily high-dose (240 mg) pramlintide. 153 In another study among 411 obese subjects, mean weight loss after 4 months for placebo was 2.8±0.8 kg, whereas for different pramlintide dosages it ranged between 3.8±0.7 and 6.1 ± 0.7 kg. 154 The main adverse effects are nausea and abdominal discomfort. Although small trials of pramlintide have been reported in adolescents with type 1 diabetes, 155, 156 no pediatric or adolescent weight loss studies have been conducted.
(h) Gut-derived hormones: (1) Ghrelin. Ghrelin, produced by gastric enteroendocrine cells, is a circulating orexigenic hormone with marked fluctuations around meals. Short-term human studies find that ghrelin infusions increase food intake. 157 The importance of hyperghrelinemia as a cause of obesity and the efficacy of inhibition of ghrelin action for obesity treatment are uncertain, as ghrelin concentrations are usually suppressed by obesity. Obese patients with the Prader-Willi syndrome (PWS) display unusually high circulating concentrations of ghrelin, 158 but treatment with octreotide (which suppresses ghrelin production) does not induce weight loss or reduce hyperphagia among these patients.
159
(2) Incretin hormones. Incretin hormones, including GLP-1, so named because they enhance glucose-stimulated insulin secretion, exert central anorectic effects in addition to their peripheral actions. Exenatide and liraglutide (GLP-1 analogs) are approved by FDA for adjunct treatment of type 2 diabetes mellitus in adults. Astrup et al. 160 reported a dose-dependent mean weight loss of 4.8-7.2 kg with liraglutide as compared with 2.8 kg with placebo after 20 weeks in obese individuals without type 2 diabetes. Others, however, reported somewhat smaller effect sizes in trials lasting up to 2 years. [161] [162] [163] [164] [165] [166] In nondiabetic subjects, placebo-controlled trials lasting up to 24 weeks found a 5.1-kg weight reduction for exenatide versus 1.6 kg for placebo. 167 One 12-week crossover study of 12 extremely obese children has reported a treatment effect of À 3.9 kg compared with behavioral intervention alone from exenatide. 168 Studies documenting the long-term safety, tolerability and efficacy of GLP-1 analogs in children and adolescents are needed.
Drugs affecting nutrient trafficking
Medications affecting digestion in the gut.
(a) Orlistat: By inhibiting gastrointestinal lipases, orlistat reduces the absorption of B30% of ingested dietary fat. Orlistat 120 mg three times a day was approved by the FDA in 2003 for management of obesity in adolescents 12-16 years of age. 169 The trials conducted to examine the efficacy of orlistat among adolescents lasted from 21 days to 15 months. [170] [171] [172] [173] [174] [175] [176] The largest study randomized 539 adolescents 12-16 years old for 52 weeks 3:1 to orlistat or placebo, with both groups receiving a multivitamin, instructions to follow a hypocaloric diet and a physical activity prescription. Approximately 35% withdrew from each group. In both arms, BMI decreased until week 12, then stabilized in the orlistat group but increased with placebo. There was an overall À 0.55 kg m À 2 decrease in BMI with orlistat versus a þ 0.31 kg m À 2 increase with placebo after 52 weeks (Po0.001). The most common adverse events were oily stools (50%), oily spotting (29%), oily evacuation (23%), abdominal pain (22%) and fecal urgency (21%). Seven participants on orlistat therapy and one child in the placebo group developed gallstones. However, only 2% of the dropouts in the orlistat group were described as due to drug-related adverse effects. 175 A secondary analysis of the same study indicated that response to treatment after 12 weeks was highly correlated with the amount of weight lost at the study end point (52 weeks), 177 suggesting that early weight loss with orlistat is a strong predictor of long-term success with the compound. Another large 6-month randomized placebo-controlled study of 200 African-American and Caucasian severely obese adolescents with obesity-related comorbid conditions published in an abstract form 178 enrolled participants in a 12-week intensive weight reduction program with a 1:1 randomization to orlistat or placebo. Those taking orlistat lost 2.9 kg compared with 0.6 kg weight reduction in the placebo group, but had no significant improvements in their comorbid conditions. Small but significant increases in serum liver enzyme concentrations were also found in orlistat-treated subjects. Orlistat has undergone two label changes because of reports of liver injury, cholelithiasis and pancreatitis; however, a cause-and-effect relationship of severe liver injury with orlistat use has not been established. 169 There is one report of acute hepatic injury in a 15-year old girl, which resolved after the medication was stopped. 179 As a lower dose (60 mg) of orlistat was approved as an over-the-counter medication for adults in 2007, accidental ingestion has been reported in children below age 5 years. Data on exposures are limited, but among 45 patients with reported outcomes, there were no cases of severe, persistent effects. 180 Ingestion of dosages as high as 5 g have been described with no serious adverse events identified. 181 Although adult patients have experienced improvements in glucose and insulin levels while taking orlistat, 182 metabolic benefits from orlistat therapy among adolescents have been reported only in a 20-person, 6 -month, open-label study by McDuffie et al. 174, 183 (a reduction in total cholesterol, low-density lipoprotein cholesterol, fasting glucose and insulin) and Chanoine et al. 175 (a decrease of À 0.51 mm Hg vs an increase of þ 1.30 mm Hg for diastolic blood pressure in orlistat vs placebo over 12 months). Because orlistat leads to decreased absorption of fat-soluble vitamins, 183 supplementation with a daily multivitamin is recommended. 184 The withdrawal rates among trials range from 0 to 35%. Orlistat should not be prescribed to patients with cholestasis or chronic malabsorption.
Orlistat produces modest weight loss and its long-term efficacy for adolescents has not been established beyond 1 year. The thricedaily recommended dosing is another significant limitation to the wide use of this drug among adolescents. Although orlistat is the only FDA-approved treatment for obesity among adolescents under the age of 16 years, it appears to offers little prospect of benefit to those with severe obesity.
(b) Cetilistat: Cetilistat is a gastrointestinal lipase inhibitor currently under investigation. 185, 186 A multicenter study of 612 adults found similar weight reductions for cetilistat and orlistat over 12 weeks among obese adults with type 2 diabetes treated with metformin, but with somewhat fewer adverse gastrointestinal events for cetilistat. 187 As weight reductions were no greater than for orlistat, it can be anticipated that cetilistat will prove of similar modest utility for weight reduction.
(c) Acarbose: Acarbose is a pseudotetrasaccharide that competitively inhibits intestinal a-glucosidase in the intestinal brush border. 188 This compromises the uptake of monosaccharides, leading to lower postprandial insulin and glucose. 188 Acarbose is approved for diabetes treatment, where it produces small weight losses in some studies among adults (0.46 kg weight loss vs 0.33 kg weight gain with placebo). [189] [190] [191] There have been no published pediatric trials for acarbose as an antiobesity drug, and given its meager efficacy in adults, it appears unlikely that acarbose will be developed for weight control. 193, 194 are investigational selective inhibitors of the sodium-dependent glucose cotransporter-2 in the renal tubule. They suppress renal glucose reabsorption, resulting in a doserelated glucosuria. 194 These drugs were developed to improve glycemic control in type 2 diabetic patients, also also induce weight loss. Among patients with type 2 diabetes, when compared with placebo, dapagliflozin induced significant improvements in glycemic control and reductions in body weight ranging from 2-5 to kg [195] [196] [197] [198] (vs 0.95-1.55 kg reductions for placebo) because of the B70 g day À 1 glucose that is excreted rather than reabsorbed in those given dapagliflozin. 194 The side effects include urinary tract and genital infections, volume depletion leading to increases in hematocrit and blood urea nitrogen and hypoglycemia in those with diabetes. In July 2011, the FDA advisory committee voted against approval of dapagliflozin for treatment of type 2 diabetes, mainly because of concerns over liver damage and a link to bladder and breast cancer. 199 No trials in obese, nondiabetic individuals have as yet been reported for these agents.
Medications affecting renal nutrient reabsorption. Dapagliflozin and Sergliflozin
Drugs affecting metabolism
Modulation of insulin action.
(a) Metformin: Metformin is a biguanide that inhibits intestinal glucose absorption, reduces hepatic glucose production and increases insulin sensitivity in peripheral insulin-targeted tissues. 200, 201 Metformin is approved for the treatment of type 2 diabetes in adults and children over age 10 years, 202 but is not approved for treatment of obesity. Its administration has been associated with modest weight loss and reduction of insulin resistance among nondiabetic adults 200 as well as prevention or delay of type 2 diabetes onset. 203 Studies on the effects of metformin as a weight-loss treatment among adolescents are few and most are short-term trials (r6 months). 205, 206 The study with longest placebo-controlled duration randomized adolescents to 48 weeks of daily metformin hydrochloride extended-release therapy or placebo in the context of a lifestyle intervention program. For this multicenter, randomized, double-blind, placebocontrolled trial, 92 obese adolescents completed a single-blind placebo 4-week run-in phase, after which the 77 subjects who demonstrated 80% medication compliance and attended at least 2 of the 3 scheduled lifestyle modification sessions, were randomized. 206 The BMI change among those who completed the trial was significantly different: À 0.9 kg m À 2 in the metformin group versus þ 2.2 kg m À 2 in the placebo arm, but metformin treatment did not produce a significant change in total fat mass, abdominal fat or insulin. The largest randomized controlled trial in younger children 207 randomized 100 severely obese, insulinresistant children aged 6-12 years to metformin or placebo for 6 months, followed by another 6 months of open-label metformin treatment. In 17% of subjects, the maximum dosage of 2000 mg day À 1 was not tolerated and had to be reduced. In an intent-to-treat analysis of those who finished the placebocontrolled phase (85% in each group), the average weight change in the metformin group was þ 1.47 kg versus þ 4.85 in the placebo group. 207 Gastrointestinal complaints (liquid or loose stools and vomiting) were significantly more prevalent among those treated with metformin, yet only two participants were reported as leaving the study because of medication intolerance. Fatigue was also significantly more likely to be reported among the metformin-treated children.
The metabolic effects of metformin in nondiabetic children and adolescents are inconsistent among studies. [206] [207] [208] [209] [210] In the available controlled trials, metformin's effect on BMI in children and adolescents varies, ranging from no change 211 to À 0.5 to À 1.5 kg m À 2 . Metformin has also been studied in the context of treatment of the polycystic ovary syndrome among adolescent girls, with observed reductions in BMI ranging from 0 to 3 kg m À 2 .
212-218
A placebo-controlled trial involving 38 adolescents with 410% weight gain on psychotropic drugs has also reported weight stabilization on metformin (mean weight change À 0.13±2.88 kg) while subjects receiving placebo continued to gain weight ( þ 4.01±6.23 kg) over 16 weeks. 219 Pooling the results of the two available studies of metformin as an agent for weight control among subjects receiving antipsychotic drugs suggests B4.1% reduction in body weight. 220 In sum, it appears that metformin has relatively modest, but significant, effects on body weight in obese children and adolescents, similar to its effects in adults. The main adverse effects of metformin are diarrhea, nausea, vomiting and flatulence, which are usually transient and mild to moderate. The odds ratio of having biochemical Vitamin B12 deficiency is reported to be 2.92 in diabetic patients on metformin treatment based on data from the National Health and Nutrition Examination Survey (NHANES), [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] , 221 yet there is no official recommendation for supplementation among these patients. Metformin is contraindicated in renal failure, should be withheld in critically ill patients and when use of imaging contrast agents is anticipated. Given its chemical similarity to phenformin, concerns were raised that metformin might predispose patients to the development of lactic acidosis; however, a recent meta-analysis in Cochrane reviews reported no evidence supporting such a relationship. 222 With its modest impact on weight, metformin does not appear particularly efficacious for weight reduction. Its ability to prevent or delay the onset of dysglycemia in children remains unproven and requires further study.
(b) Octreotide: Octreotide is a somatostatin analog that, among its manifold effects, inhibits glucose-dependent insulin secretion from pancreatic b-cells. 223 There are three studies evaluating this drug for weight loss via subcutaneous injection in pediatric patients with hypothalamic obesity, who are believed to have elevated insulin production, perhaps in response to the stimulation of hepatic glucose production that results from their hypothalamic damage. These trials demonstrated either small weight losses or reduced weight gain in octreotide-treated subjects. One study 159 has examined the effect of octreotide on patients with PWS because of its ability to suppress ghrelin. After 16 weeks of monthly octreotide administration, there was no significant change in BMI compared with placebo. 159 The major adverse effect from octreotide is development of cholelithiasis or biliary sludging in up to 44% of subjects. Transient elevation of blood glucose (15-27%), diarrhea (36-48%), abdominal pain or discomfort, flatulence, influenza-like symptoms, constipation, headache, anemia, hypertension, dizziness, fatigue, nausea and vomiting also occur. 159, 224 Octreotide cannot be recommended for treatment of obesity outside of clinical trials.
Modulation of lipolysis. Growth hormone (GH) inhibits lipoprotein lipase, increases hormone-sensitive lipase and stimulates adipocyte lipolysis. 225 GH also stimulates protein synthesis and increases fat-free mass (both muscle and bone mass). Studies in GH-deficient adults and children confirm that fat mass decreases Pharmacotherapy for childhood obesity R Sherafat-Kazemzadeh et al after GH treatment. [226] [227] [228] [229] Treatment with recombinant human GH is FDA approved for children with PWS to increase height velocity. 74 A decrease in fat mass and an increase in lean body mass are observed among both adult and pediatric patients with PWS who are given GH. [230] [231] [232] There is, however, no indication to use recombinant human GH for nonsyndromic obesity in the absence of GH deficiency. A review of clinical trials of GH administration in patients with obesity showed no better performance for recombinant human GH than for a hypocaloric diet. 233 Tumor development especially among patients who previously received irradiation for treatment of intracranial malignancies and potential adrenal insufficiency in previously unidentified hypopituitary patients are among the concerns with recombinant human GH treatment. 234 Changes in glucose metabolism may appear during long-term treatment with GH in PWS that necessitates glucose monitoring among these patients. 235 There are also concerns about GH causing greater cardiac diameters in PWS patients, although short-term studies do not support this finding. 236 Similarly, there are contradictory reports on the effect of GH treatment on respiratory symptoms (specifically sleep apnea) among PWS patients. 237, 238 Currently, the FDA has added labeling to GH products stating that GH therapy is contraindicated in patients with PWS who are severely obese or have severe respiratory impairment 239 because there may be an increased risk of sudden death. 240 Modulation of energy expenditure. There are currently no medications augmenting energy expenditure that are approved for clinical use in the treatment of obesity. Thermogenic agents are appealing in theory, but have been found either to be ineffective or, when effective, to have unacceptable adverse consequences. 241 (a) Thyroid hormones: Thyroid hormones can increase energy expenditure, but only when doses sufficient to cause hyperthyroidism are given. 242 Thus, thyroid hormone treatments are not recommended for weight loss in children or adults. 243 The thyroid hormone receptor-b1-selective thyromimetics with a safer profile with regard to cardiac and skeletal effects while exerting favorable effects on plasma cholesterol and triglyceride levels are under development. 244 So far, early phases of clinical trials have not shown much efficacy for weight loss. 245 (b) b3-Adrenergic receptor agonists: The b3-adrenergic receptor activation by b-agonists induces lipolysis and increases fatty acid oxidation and induces weight loss in rodent obesity models. Unfortunately, human trials have not found significant weight losses or effects on energy expenditure from such agents. [246] [247] [248] (c) Caffeine plus ephedrine: Ephedrine, a drug enhancing catecholaminergic tone that previously was available without a prescription, was withdrawn in 2002 by the FDA because of cardiovascular risks. The thermogenic effects of ephedrine in humans are greatly increased when methylxanthines such as caffeine, which inhibit phosphodiesterases, are coadministered. 249 In adults, an herbal caffeine/ephedrine preparation produced a weight reduction of 5.3 versus 2.6 kg with placebo; 250 larger weight reductions were reported in a case series of three patients with hypothalamic obesity. 251 One small study, which randomized 16 adolescents to caffeine plus ephedrine and 16 to placebo, reported significant weight loss (2.9 kg m À 2 vs 0.5 kg m À 2 with placebo) in a 5-month trial. 252 The side effects included nausea, insomnia, tremor, dizziness and palpitations. 253 Other studies among adults usually had small sample sizes, and the results were not consistent. [254] [255] [256] [257] [258] [259] [260] New combination therapies As body weight is defended by multiple, redundant neural mechanisms, it is reasonable to attempt obesity treatment by targeting multiple weight-regulating pathways at the same time.
The most successful of these combinations in adults was fenfluramine plus phentermine, for which weight losses were demonstrated in a cohort of 52 obese adults followed for 190 weeks. 261, 262 The efficacy of fenfluramine plus phentermine provided proof of principle that combination therapy might be useful, even though fenfluramine's adverse cardiac toxicity led to its withdrawal from clinical use.
(I) Phentermine plus topiramate: When low-dose, controlledrelease phentermine was combined with the glutamatergic and GABA-ergic antiepileptic topiramate in a large phase III study (more than 1400 participants on treatment arms with different doses), the subjects lost 10.2 kg on combination therapy versus 1.4 kg with placebo over 56 weeks. 263 The most common adverse events were dry mouth paresthesias, constipation, insomnia, dizziness and dysgeusia. Depression-and anxiety-related adverse events were also observed. The medication had favorable effects on glycemia, including progression to diabetes, improvements in lipids, blood pressure, sleep apnea and quality-of-life measures. There was also, as previously noted, a small but consistent increase in pulse rate. 148 However, medication use for obesityrelated comorbid conditions was reduced in the treatment groups compared with placebo. The overall rate of adverse effects decreased in weeks 56-108 compared with weeks 0-56; among which dry mouth, constipation and paresthesias were the most prevalent. [264] [265] [266] There were 19 pregnancies carried to term during these studies, none of which resulted in congenital abnormalities. 148 In July 2012, the FDA voted for approval of phentermine (3.75-15 mg day À 1 ) plus extended-release topiramate (23-92 mg day À 1 ) as an adjunct to diet and physical activity for treatment of obesity among adult individuals with BMI X30 or X27 kg m À 2 with at least one obesity-related comorbid condition. 267 The drug will carry a warning of potential increased risk for orofacial clefts in neonates exposed to topiramate during the first trimester of gestation and will be subject to a Risk Evaluation and Mitigation Strategy (REMS) that will restrict prescribing to trained clinicians, will require effective contraception and monthly pregnancy tests for reproductive-age women and will restrict dispensing to specific mail-order pharmacies. The company is also required to carry a long-term cardiovascular outcomes trial. 267 No randomized pediatric studies have as yet been reported.
(II) Bupropion plus zonisamide: Administration of Bupropion and Zonisamide (an anticonvulsant medication with serotonergic and dopaminergic activity) was reported to produce a weight loss of 7.2 kg versus 2.9 kg with zonizamide alone among women in short-term phase II trials, with the most important adverse effects being headache, nausea and insomnia. 73, 268 Phase II trial data collection ended in 2009; additional results of trials are not available in published form.
(III) Bupropion plus naltrexone: This proposed combination is based on the premise that naltrexone can block proopiomelanocortin neuron autoinhibition by endogenous opioids, whereas bupropion amplifies the anorexic a-melanocyte-stimulating hormone release. 269 Combination therapy is more effective than placebo or bupropion monotherapy, with almost double the number of subjects losing 45% of their body weight compared with placebo. [270] [271] [272] [273] In a modified-Intention-to-Treat LastObservation-Carried-Forward analysis, the combination resulted in 9.3±0.4% weight loss compared with 5.1±0.6% for placebo. 274 Nausea has been the most frequent adverse event, although there are also concerns about increases in blood pressure and risk for seizures from the use of bupropion. 275 Overall, there was a 46% dropout rate (vs 45% in placebo group), among which 23% was because of adverse effects (12% in placebo group), suggesting tolerability issues. 271 The FDA Endocrinologic and Metabolic Drugs Advisory Committee recommended approval of this combination drug as an antiobesity agent in December 2010, 276 but also recommended additional investigations of its potential adverse Pharmacotherapy for childhood obesity R Sherafat-Kazemzadeh et al effects. The FDA decided in February 2011 that an approval could not be granted until additional studies of long-term cardiovascular safety have been completed. 277 The manufacturer announced in February 2012 its plan to conduct the cardiovascular outcome trial required by the FDA. 278 (IV) Amylin plus leptin: A study of pramlintide plus metreleptin for 24 weeks showed a 12.7% weight loss from 24 weeks of combination therapy, a greater effect than monotherapy with either drug, with an overall weight change rate of À 0.16 and À 0.17 kg per week for metreleptin and pramlintide, and À 0.36 kg per week for the combination of the two drugs. 153, 279, 280 This combination requires injections, which may limit its extensive use. Nausea and injection site reactions were the main adverse effects. 279 (V) Pramlintide plus phentermine or sibutramine: Based on preclinical studies on dietary-induced obese rats, which showed a reduction in food intake (up to 40%) and body weight (up to 12%) after administration of amylin together with either phentermine or sibutramine, 281 the effect of these combinations have been tested among 244 nondiabetic subjects versus placebo in a 24-week, open-label trial. 282 Weight loss with either combination was B11 kg, whereas pramlintide alone resulted in À 3.6 kg weight change. The main adverse effect was nausea among all groups receiving pramlintide;elevated diastolic blood pressure and heart rate were noted in the combination therapies. for metformin-no greater than the effect sizes found for behavioral interventions. 22 Even when combined with state-ofthe-art behavioral interventions, existing pharmacotherapy among adolescents has only moderate efficacy. 31, 175, 206 Current guidelines, however, include medication in their recommended approaches to treat obese adolescents. 34, 35 The most efficacious medications for treating obesity have, unfortunately, had to be withdrawn because of adverse events. Because of the importance of the metabolic pathways involved in the regulation of energy balance, it is unlikely that any highly effective weight-loss medication will be risk free. Careful evaluation is required to balance potential known and unknown adverse effects against the potential benefits of antiobesity medications in an individual child that may include improvements in metabolic, functional and patient-reported outcomes such as quality of life.
Because obesity is a chronic condition, pediatric obesity treatments should demonstrate long-term safety and tolerability, as well as efficacy. The long-term impact of medications that have central nervous system effects or that interfere with absorption of nutrients are particularly concerning when used in growing children and adolescents. Potential teratogencity of agents expected to be used in adolescent girls, in whom any pregnancy is likely to be unplanned, are also a particular concern. The bar for consideration of using obesity medications in children should be appropriately high, and commensurate with each medication's potential benefits, safety profile and efficacy.
Why does pharmacotherapy for obesity fail so frequently due to either lack of efficacy or unacceptable adverse events or both? Obesity is a multifactorial, polygenic condition. There are myriad redundant pathways involved in detecting the body's fuel abundance, adjusting energy requirements, regulating appetite and satiety and determining body weight set-point, set against the background of an obesity-promoting environment and individual psychosocial and cultural factors. Much remains to be discovered about the etiologic heterogeneity that can be anticipated to lead to disparities in the efficacy of medications among study participants. The value of using a specific treatment directed toward an established obesity-causing mechanism has already been shown for children and adolescents with one extremely rare form of monogenic obesity: leptin is remarkably successful to treat the obesity of leptin deficiency. 101, 103 It seems likely, therefore, that once a more complete differential diagnosis for pediatric obesity can be established based on genetic (and perhaps epigenetic) and phenotypic characteristics, new drug trials can be initiated that select patients who are more likely to respond to a given medication.
The belief that most patients with significant obesity have multiple contributing genetic loci is supported by recent genomewide association studies. [283] [284] [285] Many of the identified genotypes are associated with early obesity traits. Thus, for many, if not most children, targeted combination therapies that affect multiple impaired weight-regulating systems are likely to be required to improve body weight and avoid obesity's comorbid conditions. The ability of combination drug therapy to ameliorate pediatric obesity safely remains to be demonstrated in meticulously designed clinical trials with adequate power. Dysregulation of other metabolic systems that have redundancy in their control mechanisms has been amenable to such an approach. For example, hypertension is now commonly treated with pharmacotherapeutic regimens that are directed against three or more different blood pressure control points. 286 If novel single or combination therapies are to be tested in the future for their impact on pediatric obesity and its complications, the clinical trials would be most useful if they are conducted as randomized, placebo-controlled trials, have carefully justified subject selection criteria and outcomes, are adequately powered to account for potentially high attrition rates, 22, 287 have long-term follow-up and are reported according to the CONSORT statement. 288 Obesity is a chronic condition but most pediatric studies have a short duration (6 to 12 months); thus, there is little information available about the effectiveness and adverse effects from long-term use of obesity medications in children and adolescents. Appropriate short-and long-term outcomes need to be identified for pediatric populations, rather than necessarily using adult-oriented outcomes. Although a good case can be made for using change in BMI rather than change in BMI percentile or BMI s.d. score as the primary outcome in weight-loss studies among obese children and adolescents, 289, 290 age-specific metrics are likely to be appropriate for metabolic and behavioral outcomes. Meta-analyses on clinical trials among adults show that there is usually little weight loss reported beyond the typical plateau at 6 months, which is followed by weight regain during the next few years. 291, 292 Primary prevention and lifestyle intervention for those already overweight or obese are the foundations for weight management for children, adolescents and adults. For obese youth who are unable to achieve sufficient weight loss with lifestyle interventions alone, adjunctive use of more intensive treatments, including pharmacotherapy, may be appropriate. However, the search for obesity medications that are safe for long-term use, sufficiently efficacious to promote enough weight loss to improve health and have a favorable risk-benefit ratio remains elusive. Nevertheless, there is great hope that development of more effective, etiologybased antiobesity therapies for children and adults will prove possible.
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